Ovarian hyperstimulation syndrome (OHSS) is a serious complication of ovarian stimulation protocols. Currently, no curative therapy exists and the main preventive option is cycle cancellation. Gonadotrophin-releasing hormone (GnRH) antagonist administration in the luteal phase was recently proposed as a new approach for the management of patients with established severe OHSS. Three polycystic ovarian syndrome patients undergoing IVF treatment developed severe OHSS, diagnosed 6 days after oocyte retrieval. On day 6, the patients underwent blastocyst transfer and received GnRH antagonist for 4 days, combined with luteal phase support using exogenous oestradiol and progesterone. Two patients had successful pregnancies that resulted in births of healthy infants, while one patient had a biochemical pregnancy. In all patients, established severe OHSS regressed to a moderate form of the syndrome, no pregnancy-induced life-threatening OHSS was observed, while a short monitoring period was required at an outpatient level, avoiding the need for patient hospitalization. This is the first report in the literature on GnRH antagonist administration in the luteal phase, combined with embryo transfer and exogenous oestradiol and progesterone supplementation. This novel treatment was effective in the regression of established severe OHSS, and resulted in the birth of healthy infants.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rbmo.2009.09.021 | DOI Listing |
Hum Fertil (Camb)
December 2025
Developmental Biology and Medicine, School of Medical Sciences, The University of Manchester, Manchester, United Kingdom.
This British Fertility Society (BFS) Policy and Practice guideline aims to support clinicians in preventing ovarian hyperstimulation syndrome (OHSS) in patients undergoing gonadotropin ovarian stimulation. A systematic literature search of the medical databases was performed. The Guideline Development Group (GDG) identified the risk factors of OHSS before and during ovarian stimulation.
View Article and Find Full Text PDFAm J Transl Res
November 2024
Reproductive Medicine Center, Hunan Provincial Maternal and Child Healthcare Hospital Changsha 410008, Hunan, China.
Objective: To compare the safety and effectiveness between long-term GnRH agonist plus HCG (dual trigger) and HCG trigger alone in high ovarian responders.
Methods: A retrospective study was conducted on clinical data from 314 cases of high ovarian response who underwent in-vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) treatment at Hunan Provincial Maternal and Child Healthcare Hospital from July 2018 to January 2023. Participants were divided into two groups based on their triggering regimen: the Combined treatment group (GnRH agonist + HCG) and the HCG group (HCG alone).
J Matern Fetal Neonatal Med
December 2024
Centre for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China.
Objective: maturation (IVM) is an advanced technique and an alternative to conventional fertilization (IVF). It is safe, effective, and cost-effective in patients with polycystic ovary syndrome (PCOS). However, no clinical guidelines state that IVM could work without compromised pregnancy outcomes in patients with PCOS.
View Article and Find Full Text PDFJ Pers Med
August 2024
School of Law, Polytechnic University of Marche, 60121 Ancona, Italy.
J Stroke Cerebrovasc Dis
January 2025
Clinical and Translational Neuroscience Unit, Department of Neurology, Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, 520 East 70th Street, Starr Pavilion, 607, New York, NY, 10021, USA. Electronic address:
Background: Case reports describe arterial thrombosis including ischemic stroke associated with severe ovarian hyperstimulation syndrome (OHSS), but the prevalence of major ischemic events during or shortly after OHSS is unknown.
Methods: Using publicly available administrative datasets in the United States between 2015 and 2020, we conducted two separate cross-sectional studies of patients with OHSS. We included all patients with OHSS.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!